Clinical Trial Update: A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/Phase 3 trial evaluated intravenous N-acetylcysteine for management of antituberculous drug-induced hepatitis (drug-induced liver injury).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Drug-induced Liver Injury

Drugs mentioned

• N-acetylcysteine (intravenous) (N-acetylcysteine)

Snippet

Sponsor: University of Cape Town | Conditions: Drug-Induced Liver Injury | Phase 2, Phase 3 | Status: COMPLETED